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sociated with mental status disorder (delirium or abulia; 
OR = 4.59; 95% CI = 1.41–14.89) and negatively associ-
ated with headache (OR = 0.03; 95% CI = 0.00–0.32). Pre-
sentation as isolated intracranial hypertension was as-
sociated with admission delay of more than 4 days
(OR = 2.63; 95% CI = 0.97–7.14). Papilloedema was asso-
ciated with an admission delay of more than 13 days (OR 
= 4.69; 95% CI = 1.61–13.61). There was no association 
between admission delay and the proportion of antico-
agulated patients. The interval between onset of symp-
toms and start of anticoagulation was shorter in patients 
admitted earlier (p = 0.0001, for either admission within 
24 h, 4 or 13 days). There is a considerable delay until 
the clinical picture associated with CVT is recognised as 
justifying hospital admission, especially when patients 
present with symptoms identical to isolated intracranial 
hypertension syndrome. 
 Copyright © 2005 S. Karger AG, Basel 
 Factors infl uencing early hospital referral and admis-
sion have been described for several stroke types  [1–6] , 
including subarachnoid haemorrhage  [7–10] , but not for 
cerebral vein and dural sinus thrombosis (CVT). This 
type of stroke is far less frequent and has more diverse 
presenting patterns than arterial stroke, and these factors 
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 Abstract 
 Factors infl uencing early hospital admission have been 
described for several stroke types but not for cerebral 
vein and dural sinus thrombosis (CVT). CVT is more dif-
fi cult to diagnose than arterial stroke; delay in hospital 
admission may postpone CVT treatment. The purposes 
of this study were: (1) to describe the delay between the 
onset of symptoms and hospital admission of patients 
with CVT, and (2) to identify the variables that infl uence 
that delay. We registered the interval (days) between the 
onset of symptoms and hospital admission in 91 con-
secutive patients admitted to 20 Portuguese hospitals 
between June 1995 and June 1998. We also studied the 
impact of admission delay on treatments (prescription 
of anticoagulants and the number of days elapsed be-
tween the onset of symptoms and start of anticoagula-
tion and admission). Median admission delay was 4 
days. Twenty-two (25%) patients were admitted within 
24 h. Two thirds of the patients were admitted within 7 
days and 75% within 13 days. In multiple logistic regres-
sion analysis, admission within 24 h was positively as-
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complicate its recognition and delay clinical suspicion 
and diagnosis. On the other hand CVT can be readily di-
agnosed using modern neuroimaging techniques, either 
MRI/MR venography or CT venography. Intravenous or 
subcutaneous anticoagulation improve the prognosis of 
acute CVT  [11] . Local thrombolysis is selectively used in 
experienced centres in severe cases  [12] . The clinical 
course of CVT is often unpredictable and in many pa-
tients the clinical picture worsens after diagnosis  [13] . 
Delay in hospital admission and of CVT diagnosis post-
pones appropriate treatment. 
 The purpose of this study was twofold: (1) to describe 
the delay between the onset of symptoms and hospital 
admission of patients with CVT, and (2) to identify the 
variables that infl uence that delay, i.e. to test the hypoth-
esis that more severe clinical presentation patterns have 
a shorter admission delay. 
 Method 
 We registered the interval (days) between the onset of symptoms 
and hospital admission in 91 consecutive patients admitted to 20 
Portuguese hospitals between June 1995 and June 1998 (all patients 
were also included in the VENOPORT study  [14] ). All cases were 
confi rmed by intra-arterial or MRI/MR venography or angiogra-
phy. 
 Possible explanatory variables of the admission delay included 
were centre, age and gender, location of the occluded sinus/vein, 
parenchymal lesion on admission CT/MRI (infarct/oedema and 
haemorrhage), symptoms and signs at admission, presentation syn-
dromes (isolated intracranial hypertension, defi ned as any combi-
nation of headache, vomiting and papilloedema with or without VI 
nerve palsy vs. other presentation syndromes) and risk factors for 
CVT. 
 We analysed the impact of admission delay on the prescription 
of anticoagulants and the number of days elapsed between the on-
set of symptoms and start of anticoagulation and between admis-
sion and start of anticoagulation. Outcome was assessed with the 
modifi ed Rankin Scale (mRS)  [15] at hospital discharge (median 
18 days) and at the end of follow-up (median 22 months; range 
3–36 months)  [16] . Unfavourable outcome was defi ned as an mRS 
3–6. 
 Statistics 
 We dichotomised admission delay according to the median of 
the distribution. A second subgroup division contrasted the quar-
tiles with the shortest admission delays (ultra-early admission) with 
those of the remaining patients, and the quartile with the longest 
(delayed) admission delays with those of the remaining patients. 
To test for bivariate associations between categorical variables we 
used    2  with Yates correction when necessary or Fisher exact test. 
No correction for multiple testing was performed. To evaluate the 
association between continuous variables and two conditions of a 
categorical variable we used t test or median test, depending on the 
normality of the distribution of the continuous variable. Variables 
with a trend (p  ! 0.20) to be associated with admission delay on 
bivariate analysis were entered in a multiple logistic regression, 
with computation of OR and 95% CIs. 
 Results 
 Data on admission delay was available for 90 patients. 
Distribution of admission delay is shown in  fi gure 1 . As 
expected the distribution was skewed, with a median of 
4 days. Twenty-two (25%) patients were admitted within 
24 h and 75% within 13 days. Two thirds of the patients 
were admitted within 7 days. 
 Variables positively and negatively correlated in bi-
variate analysis with an admission delay of 1 day or less 
(ultra-early admissions), 4 days or less, and 13 days (de-
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 Fig. 1. Distribution of the interval (days) 
between onset of symptoms and hospital 
admission. 
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layed admissions are shown in  table 1 ). There was no as-
sociation between admission delay and centre, location 
of the occluded sinus/vein, and risk factors for CVT. In 
logistic regression analysis, admission within 24 h was 
positively associated with mental status disorder (deliri-
um or abulia; OR = 4.59; 95% CI = 1.41–14.89) and neg-
atively associated with headache (OR = 0.03; 95% CI = 
0.00–0.32). Presentation as isolated intracranial hyper-
tension was associated with admission delay of more 
than 4 days (OR = 2.63; 95% CI = 0.97–7.14). Papillo-
edema was associated with admission delay of more than 
13 days (OR = 4.69; 95% CI = 161–13,61). 
 As far as the infl uence of admission delay on treatment 
is concerned, there was no association between admission 
delay and the proportion of anticoagulated patients: 20 
anticoagulated out of 22 patients admitted within 24 h 
(91%) vs. 55/68 admitted later (81%; p = 0.27); 34 anti-
coagulated out of 43 patients admitted within 4 days 
(79%) vs. 41/47 admitted later (87%; p = 0.30); 56 anti-
coagulated out of 68 admitted within 13 days (82%) vs. 
19/22 (86%; p = 0.766) admitted later. The interval be-
tween onset of symptoms and start of anticoagulation was 
shorter for patients admitted earlier (p = 0.0001, median 
test, for either admission within 24 h, 4 or 13 days). How-
ever there were no differences in the interval between 
admission and start of anticoagulation between patients 
admitted within or after each of those time windows. 
 Discussion 
 In this cohort mean delay between onset of symptoms 
and hospital admission was 4 days, though with a wide 
variation range. Presentation as isolated intracranial hy-
pertension and older age were associated with an in-
creased delay in hospital admission. Not surprisingly, an-
ticoagulation was started earlier in patients with early 
presentation, but the proportion of anticoagulated pa-
tients was not infl uenced by the admission delay. 
 This is the fi rst systematic study to describe and ana-
lyse the admission delay of CVT patients; however, it has 
some limitations. The onset of symptoms in CVT can be 
Table 1. Distribution of potential predictors by admission delays
Admission delay
^1 day ^4 days >13 days
n % p n % p n % p
Male
Age >45 years 
Admission CT/MRI
Infarct/oedema
Haemorrhage
Any lesion
Symptoms/signs
Isolated intracranial hypertension syndrome
Headache
Papilloedema
Stupor/coma
Mental status disorder
Motor defi cit
Seizure
Aphasia
Cerebral deep venous system thrombosis
Outcome at fi nal follow-up
Death
Dependency (mRs 3,4,5)
Independent (mRs 2)
Complete recovery (mRs 0,1)
4
3
9
8
10
2
16
5
2
9
10
10
3
1
2
0
2
18
17
16
30
30
20
 6
19
15
20
47
33
34
25
14
29
 0
33
24
n.s.
n.s.
n.s.
n.s.
n.s.
0.004
0.001
n.s.
n.s.
0.02
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
10
7
16
15
23
9
41
11
7
13
20
17
8
6
4
1
3
39
 42
 37
 53
 56
 56
 29
 49
 32
 70
 68
 67
 59
 67
 86
 57
100
 50
 52
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
0.003
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
 6
 6
 9
 8
10
12
22
15
 2
 3
 6
 7
 1
 1
 3
 0
 1
18
25
32
30
30
24
39
27
44
20
14
20
24
 8
14
43
 0
17
24
n.s. 
n.s.
n.s.
n.s.
n.s.
0.02
n.s.
0.001
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n = Number with condition; % = calculated by dividing the number with the condition and within delay in-
terval by the total number with that condition.
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gradual, the precise day of onset being diffi cult to defi ne 
and infl uenced by recall bias. After hospital admission it 
may take a few days to reach the diagnosis and this will 
further delay starting appropriate treatment. Unfortu-
nately we did not record the day of the confi rmation of 
the diagnosis. However the delay in starting anticoagula-
tion after admission was similar in all patients (indepen-
dent of ultra-early, early or late admission). This is an 
indirect indication that the time to diagnosis after admis-
sion was not infl uenced by admission delay. We also did 
not collect information on medical encounters previous 
to hospital admission or on the patients’ own view of their 
health problem. 
 A quarter of the patients were admitted on the day of 
symptoms onset and two thirds were admitted within a 
reasonable interval of 1 week. Only 15% entered hospital 
more than 3 weeks after the fi rst symptoms. Factors in-
fl uencing early presentation can be related to the patient, 
the disease or the health care organisation; these three 
factors contribute to admission delays in CVT patients. 
The wide variation in admission delays refl ects the pa-
tients’, their proxies’ and physicians’ diffi culties in recog-
nising the seriousness of the condition. Presentation as 
isolated intracranial hypertension syndrome and older 
age were independent predictors of delayed admission. 
When experiencing a rather common symptom (such as 
headache), patients may delay seeking medical attention 
and physicians may be reluctant to order an MRI as fi rst-
line imaging procedure. The relative rarity of CVT makes 
it less likely to be included in the differential diagnosis 
list of a general practitioner or emergency physician ex-
amining a patient complaining of a headache. They prob-
ably do not perform fundoscopy routinely. The fi nding of 
papilloedema may trigger admission, but papilloedema 
may take days to develop. Conceivably, the need to per-
form MRI to confi rm the diagnosis delays the diagnosis 
of CVT because MRI is less readily available and more 
costly than CT. 
 Admission delay had no impact on the prescription of 
anticoagulants, although patients who came earlier also 
started treatment sooner. Breteau et al.  [17] registered the 
delay (median 5 days) between onset of symptoms and 
starting heparin in a series of 55 CVT patients. Delay in 
starting heparin had an infl uence on outcome. In Ein-
häupl et al.’s  [18] trial heparin was started a mean of 32.5 
days after the initial symptoms, while in the nadroparin 
trial  [19] the mean delay from symptoms onset to ran-
domisation was 10 days. In a systematic review of throm-
bolysis in CVT  [12] , the outcome of patients treated be-
fore and 1 week after onset was similar. In their series of 
18 CVT patients Rondepierre et al.  [20] also found no 
association between admission delay and diagnosis and 
outcome. This is in accordance with our previous fi nding 
that admission delay was not associated with a worse out-
come  [14, 15] . One factor contributing to this counter-
intuitive result is the very early admission of patients with 
more dramatic and severe clinical presentations who 
have a less favourable prognosis. Therefore there is cur-
rently no convincing evidence that delay in establishing 
the diagnosis or in starting treatment infl uences out-
come. 
 The results of this investigation must be confi rmed in 
a larger sample, preferably multinational, to decrease lo-
cal practice bias. This is particularly important for our 
fi nding that admission delay does not seem to impact on 
outcome. If possible, other factors should be investigated, 
including the intra-hospital delay in diagnosis and factors 
leading the patient to look for medical attention, medical 
contacts and diagnosis before CVT confi rmation. 
 Our results have some implications for practice. There 
is considerable delay in recognising that the clinical pic-
ture associated with CVT is serious enough to justify hos-
pital admission. Headaches are the most frequent symp-
tom of CVT, but CVT presenting as headache or intra-
cranial hypertension syndrome is more diffi cult to 
diagnose. CVT should be considered a potential diagnosis 
in patients presenting new-onset headaches, or headaches 
of a type or severity different to their usual ones. Early 
recognition of CVT hastens commencement of appropri-
ate treatment and also speeds the search for treatable, 
potentially health-threatening risk factors and associated 
conditions. At present, MRI must be performed to con-
fi rm CVT. D-dimers can be used as a screening tool for 
CVT  [21] , although there is a possibility of false negatives 
 [22] . A sensible sequence to exclude CVT in patients pre-
senting with headaches would be to perform CT and D-
dimers in all patients and to request MR only for those 
with direct or indirect signs of CVT on CT and/or high 
D-dimers titers. It remains to be seen which strategy is 
more cost effective: using this diagnostic sequence or re-
ferring patients with such types of headaches directly for 
MRI to screen for CVT (and other intracranial dis-
eases). 
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